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ABSTRACT
Several studies over the last few decades have shown that antibiotic resistance mechanisms frequently confer a fitness cost and
that these costs can be genetically ameliorated by intra- or extragenic second-site mutations, often without loss of resistance.
Another, much less studied potential mechanism by which the fitness cost of antibiotic resistance could be reduced is via a
regulatory response where the deleterious effect of the resistance mechanism is lowered by a physiological alteration that
buffers the mutational effect. In mycobacteria, resistance to the clinically used tuberactinomycin antibiotic capreomycin
involves loss-of-function mutations in rRNA methylase TlyA or point mutations in 16S rRNA (in particular the A1408G
mutation). Both of these alterations result in resistance by reducing drug binding to the ribosome. Here we show that
alterations of tlyA gene expression affect both antibiotic drug susceptibility and fitness cost of drug resistance. In particular,
we demonstrate that the common resistance mutation A1408G is accompanied by a physiological change that involves
increased expression of the tlyA gene. This gene encodes an enzyme that methylates neighboring 16S rRNA position C1409,
and as a result of increased TlyA expression the fitness cost of the A1408G mutation is significantly reduced. Our findings
suggest that in mycobacteria, a nonmutational mechanism (i.e., gene regulatory) can restore fitness to genetically resistant
bacteria. Our results also point to a new and clinically relevant treatment strategy to combat evolution of resistance in
multidrug-resistant tuberculosis. Thus, by utilizing antagonistic antibiotic interactions, resistance evolution could be reduced.
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INTRODUCTION
One of the key factors determining the success of an antibi-
otic-resistant bacterial clone in a clinical setting is the impact
of the resistance mechanism on the fitness of the bacteria.
Several studies have shown that resistance typically is associ-
ated with a reduction in fitness (Andersson and Levin 1999;
Andersson and Hughes 2010), even though a few exceptions
exist (Bottger et al. 1998; Sander et al. 2002), and that resistant
mutants generally grow slower and have reduced virulence
and survival when compared to their susceptible siblings.
Studies of streptomycin resistance inMycobacterium tubercu-
losis were the first to combine data on the frequency of mo-
lecular resistance determinants in clinical isolates in vivo with
in vitro experimental data on the genetics and costs associat-
ed with resistance. In these clinical isolates, an inverse corre-
lation was observed between the frequency of a resistance
mutation and its fitness cost, i.e., the most costly mutations
were also the most rare among clinical isolates (Bottger
et al. 1998; Sander et al. 2002).
InM. tuberculosis, the etiologic agent of tuberculosis, drug
resistance is exclusively due to chromosomal alterations that
affect either the drug target itself or bacterial enzymes mod-
ifying the drug (for review, see Bottger and Springer 2008).
Injectable antibiotics such as the aminoglycosides kanamycin
and amikacin and the tuberactinomycins capreomycin and
viomycin are key second-line drugs for the treatment of mul-
tidrug-resistant tuberculosis (MDR TB) disease (for review,
see Falzon et al. 2011). These antibiotics inhibit protein
synthesis by binding to the small ribosomal subunit
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(Shcherbakov et al. 2010; Stanley et al. 2010). As all four
drugs share the same molecular target and bind to a similar
location in the ribosome, cross-resistance is frequently
observed (McClatchy et al. 1977; Maus et al. 2005a;
Feuerriegel et al. 2009; Jugheli et al. 2009; Akbergenov et al.
2011; Sirgel et al. 2012). Resistance to the tuberactinomycin
antibiotics capreomycin and viomycin involves two mecha-
nisms, both of which result in reduced binding of the antibi-
otics to the 30S subunit of the ribosome: loss-of-function
mutations in rRNA methylase TlyA (Maus et al. 2005b;
Monshupanee et al. 2012) and point mutations in 16S
rRNA (Akbergenov et al. 2011), in particular at position
1408. While loss-of-function mutations in rRNA methylase
TlyA only affect tuberactinomycins but not aminoglycosides
(Maus et al. 2005b), point mutations in 16S rRNA in general
confer cross-resistance to both tuberactinomycins and ami-
noglycosides (Sirgel et al. 2012; Reeves et al. 2015).
Fitness costs conferred by resistance mutations can be
reduced by compensatory evolution, where second-site
mutations reduce or completely ameliorate the cost, often
without loss of resistance (Andersson and Levin 1999;
Andersson and Hughes 2010). Such genetically based com-
pensatory evolution has been demonstrated with various
combinations of bacteria and resistance mechanisms in vitro,
in animal models and in humans and often occurs rapidly
and with high efficiency. It is expected that compensation
will result in stabilization of the resistance in the bacterial
population (Andersson and Levin 1999; Andersson and
Hughes 2010). In M. tuberculosis, secondary-site compensa-
tory mutations have been demonstrated in clinical isolates re-
sistant to aminoglycosides. Thus, specific point mutations in
rRNA that confer aminoglycoside resistance can be compen-
sated by mutations that restore rRNA secondary structure
(Shcherbakov et al. 2010). Similarly, there is circumstantial
evidence for compensatory mutations restoring fitness for
isoniazid, and rifampicin resistant mutants (Sherman et al.
1996; Comas et al. 2012; Meftahi et al. 2016).
Another potential mechanism of compensation could be
by alterations in gene regulation where the initial cost of the
resistancemechanism is reduced by a physiological alteration.
Such mechanisms would generally be much more difficult
to identify since the physiological response might be very
rapid and not involve any genetic changes. One rare example
illustrating such a physiological response was provided by
the studies of Olivares et al. (2014), who
showed that the costs of overexpressing
the multidrug efflux pump MexEF-
OprN (a proton/substrate antiporter sys-
tem) in Pseudomonas aeruginosa can be
compensated by an unknownmechanism
that causes a metabolic rewiring to in-
crease aerobic respiration and reduce
the deleterious effects of an increased
proton influx and acidification due to
the overexpressed efflux pump.
In this study, we show thatmycobacterial adaptation to an-
tibiotic exposure and mutational fitness cost involves alter-
ation of tlyA gene expression. In particular, we demonstrate
that the substantial fitness cost associated with the common
rRNA resistance mutation A1408G can be reduced by up-
regulation of the tlyA rRNA methylase. The TlyA methylase
modifies the neighboring position 1409, reducing the cost
of the A1408G mutation while concomitantly also reducing
the resistance level.
RESULTS
Mutant ribosomes with the A1408G mutation in 16S
rRNA are more resistant in cell-free in vitro translation
than in vivo
During analysis ofM. smegmatismutants resistant to capreo-
mycin and viomycin, we observed an unexpected discrepancy
in drug susceptibility for thewild type versus the A1408Gmu-
tant when comparing whole-cell MIC determinations with
drug susceptibility as determined in cell-free ribosomal trans-
lation assays. In a standard MIC assay, the A1408G mutant
bacteria showed an eight- to 16-fold increase in resistance
for capreomycin when compared to the susceptible wild
type bacteria (Table 1). However, when resistance was ana-
lyzed in an in vitro translation system based on cellular ex-
tracts from susceptible wild type and resistant A1408G
mutant bacteria, there was a 100-fold difference in the level
of resistance (Table 2; Supplemental Fig. 1). Thus, for both
capreomycin and viomycin the relative resistancewas approx-
imately 10-fold higher when analyzed at the ribosomal target
when compared to the MIC determined using intact cells. In
contrast, for the tlyA deletion mutant no such discrepancy in
tuberactinomycin susceptibility between whole-cell MIC and
ribosomal IC50 was observed. As a control, drug susceptibility
to the aminoglycoside amikacin was determined, and for both
MIC and ribosomal translation assays the A1408G mutation
increased resistance >1000-fold, and as expected, inactivation
of tlyA did not affect drug susceptibility. Significantly, a sim-
ilar fourfold increase inMIC levels for capreomycin conferred
by the A1408G mutation was also observed in clinical M. tu-
berculosis isolates (Table 3). An implication of these findings is
that in the living cell the tuberactinomycin resistance levels
are reduced by an unknown mechanism.
TABLE 1. Drug susceptibility (MIC, µg/mL) of recombinant M. smegmatis strains
Genotype Capreomycin
Relative
resistance Viomycin
Relative
resistance Amikacin
Relative
resistance
Wild type 8 – 4 – 0.25 –
ΔtlyA 32–64 4–8 8–16 2–4 0.25 1
A1408G 64–128 8–16 4–8 1–2 >1024 >1000
ΔtlyA
A1408G
1024 128 32–64 8–16 >1024 >1000
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In response to capreomycin, cells down-regulate TlyA-
mediated methylation of 16S and 23S rRNA resulting
in decreased drug susceptibility
Previous studies showed that the TlyA methylase modifies
position 1409 in 16S rRNA and position 1920 in 23S
rRNA and that inactivation of TlyA-dependent methylation
confers resistance to capreomycin and viomycin (Johansen
et al. 2006). Furthermore, as reported below, we observed
that incubation with capreomycin during bacterial growth
resulted in a reduced post-transcriptional modification of
rRNA at TlyA-dependent sites (1409 in 16S and 1920 in
23S). Based on these observations and the discrepancy be-
tween MIC values in whole cells (eight- to 16-fold increase
in A1408G mutant compared to wild type) and susceptibility
in cell-free translation (100-fold increase in A1408G mutant
compared to wild type), we hypothesized that alterations in
TlyA-dependent rRNA methylation modulated drug suscep-
tibility. Thus, in the wild type, the presence of drug should
result in a down-regulation of TlyA-mediated methylation
and cause an increased resistance. Conversely, the A1408G
mutation in the absence of drug should result in an increased
TlyA-expression and a concomitant reduction in resistance.
A prediction from this reasoning is that inactivation of the
tlyA gene should have the same effect as pregrowth in the
presence of capreomycin.
To test this idea, we first compared the drug susceptibility
of ribosomes prepared from wild-type cells pregrown in the
presence of capreomycin and corresponding tlyA-inactivated
mutants. We preincubated whole cells with capreomycin and
then prepared ribosomes to measure activity in cell-free
translation and level of rRNA methylation. Preincubation
with drug resulted in increased resistance as well as reduced
post-transcriptional modification of residues 1409 in 16S
rRNA and 1920 in 23S rRNA. Thus, preincubation of wild
type cells with capreomycin resulted in a dose-dependent
decrease of tuberactinomycin susceptibility in wild type M.
smegmatis, as determined in cell-free ribosomal translation
assays, and a 20 h preincubation with 1 µg/mL capreomycin
resulted in IC50 values similar to the ΔtlyAmutant. Similarly,
preincubation with capreomycin increased tuberactinomycin
resistance of the A1408G mutant as assessed in cell-free
translation assays. Thus, a 20 h preincubation of A1408G
mutants with 1 µg/mL capreomycin resulted in IC50 values
similar to that of the A1408G ΔtlyA dou-
ble mutant. As predicted, preincubation
with capreomycin did not affect tuberac-
tinomycin resistance in the ΔtlyAmutant
nor in the A1408G ΔtlyA double mutant
(Table 4, compare with Table 2; see
Supplemental Figs. 2, 3).
The increased resistance in cell-free
translation was associated with a reduced
post-transcriptional modification of resi-
dues 1409 in 16S rRNA and 1920 in 23S
rRNA (Fig. 1). These experiments demonstrated that in the
presence of low capreomycin levels, TlyA-dependent rRNA
modificationwasreduced, andas a result, ribosomal resistance
was increased. In summary, inactivation of the tlyA gene had
the same effect as pregrowth in the presence of capreomycin.
Increased TlyA expression reduces resistance in the
A1408G mutant and concomitantly increases fitness
A second prediction of the hypothesis that TlyA-dependent
rRNA methylation modulates resistance in the A1408G mu-
tant is that TlyA expression is increased in the presence of the
A1408G mutation and results in reduced resistance. We per-
formed two experiments to test this prediction. First, we ex-
amined whether TlyA levels were increased in the A1408G
mutant. Results shown in Figure 2A demonstrate that levels
of tlyA mRNA were increased approximately sevenfold in
the A1408G M. smegmatis mutants when compared to the
wild type. In addition, and to examine whether our findings
observed in M. smegmatis also apply to the pathogen M. tu-
berculosis, we studied tlyA gene expression in the laboratory
strain M. tuberculosis H37Rv. Spontaneous A1408G mutants
were obtained by selective plating. Compared to the wild type
strain, A1408G mutants showed increased levels of tlyA
mRNA (Fig. 2B). Finally, we studied clinical isolates ofM. tu-
berculosis. Compared to fully drug susceptible clinical iso-
lates, aminoglycoside-resistant clinical isolates of M.
tuberculosis with the corresponding A1408G mutation on av-
erage showed a fourfold increase in levels of tlyAmRNA (Fig.
2C). As expected for a regulatory, nonmutational compensa-
tory mechanism, the levels of tlyAmRNA expression in clin-
ical A1408G M. tuberculosis isolates varied significantly both
between different isolates and within a single isolate (see Fig.
TABLE 2. Drug susceptibility (IC50, µM) of M. smegmatis ribosomes
Genotype Capreomycin
Relative
resistance Viomycin
Relative
resistance Amikacin
Relative
resistance
Wild type 0.03 ± 0.01 – 0.03 ± 0.01 – 0.05 ± 0.01 –
ΔtlyA 0.19 ± 0.02 8 0.20 ± 0.05 6 0.08 ± 0.02 1–2
A1408G 2.4 ± 0.5 100 0.42 ± 0.07 14 270.17 ± 32.8 >1000
ΔtlyA
A1408G
11 ± 1.7 450 1.2 ± 0.15 40 374.41 ± 47.4 >1000
TABLE 3. Drug susceptibility (MIC, µg/mL) of M. tuberculosis
clinical isolates (wild type and A1408G mutant)a
Genotype Capreomycin Amikacin
Wild type 1.25–2.5 1
A1408G 5–10 >128
aThree clinical isolates each of wild type and A1408G mutant
were tested.
Freihofer et al.
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2C, inset). To corroborate the conclusion that a nonmuta-
tional mechanism is involved in up-regulation of tlyA
mRNA levels in the A1408G mutant, we sequenced the tlyA
promoter region (position 1915029–1915526) and the 5′ up-
stream region of tlyA (position 1917769–1917939) in all M.
tuberculosis strains investigated (H37Rv in vitro selected
A1408G mutants, clinical wild type and A1408G isolates);
no mutations were found.
As a second test, we determined the effect of preincubation
with capreomycin on MIC levels in whole cells. As expected,
pregrowth in the presence of capreomycin did not affect MIC
levels in the ΔtlyA mutant. In contrast, and as predicted on
the basis of increased tlyA mRNA levels, preincubation in-
creased the MICs of capreomycin and viomycin in the
A1408G mutant to the same extent as in-
activation of the tlyA gene (Table 5).
We finally studied whether in-
activation of the tlyA gene affected the fit-
ness cost of the A1408G mutation in
addition to the increase in resistance.
Measurements of fitness as growth rate
in vitro showed that loss of TlyA function
comes without any measurable fitness
cost whereas the A1408G mutation car-
ried a fitness cost of 5%. In the presence
of a loss of function of tlyA, the A1408G
mutation confers a fitness cost of 10%
per generation (Fig. 3), demonstrating
that a functional TlyA methylase signifi-
cantly reduces the fitness cost of the
A1408G mutation. Overall, these results
suggest that in the A1408G mutant, in
the absence of drug, the TlyA enzyme is
up-regulated, resulting in sustained
rRNA methylation and partial ameliora-
tion of the fitness cost of the A1408G re-
sistance mutation.
DISCUSSION
Essentially all types of organisms can re-
spond and adapt to altered environmen-
tal conditions by various regulatory and
physiological changes. Similarly, changes
in gene expression and cell physiology
can occur in response to mutational al-
terations, and there are numerous exam-
ples of how mutations might cause
alterations in gene expression (Felix and
Barkoulas 2015; Ho and Zhang 2016;
Naseeb et al. 2016). However, whether
these changes are adaptive and homeo-
static in the sense that they act to buffer
the negative effect of the mutation and
thereby restore fitness, or whether they
are only downstream pleiotropic effects of no adaptive value
is more difficult to say. The reason for this is that to distin-
guish between these two (not mutually exclusive) possibilities
one has to examine how the mutation affects fitness both in
the presence and absence of the observed change in gene ex-
pression, which might be difficult to achieve experimentally.
Here we report on a compensatory effect that involves a
gene regulatory response that dampens the fitness cost of a
mutation that confers resistance to tuberactinomycins, sec-
ond-line drugs for the treatment of MDR-TB. Our results
suggest that the fitness cost of the A1408G mutation, a mu-
tation that confers cross-resistance to aminoglycosides and
tuberactinomycins, can be reduced by an increased expres-
sion of the tlyA gene, and associated sustained methylation
TABLE 4. Drug susceptibility (IC50, µM) of M. smegmatis ribosomes isolated from strains
preincubated with capreomycin for 20 h
Genotype Preincubation Capreomycin Viomycin Amikacin
Wild type – 0.02 ± 0.01 0.02 ± 0.01 0.04 ± 0.02
Wild type 0.5 µg/mL CAP 0.10 ± 0.04 0.08 ± 0.03 0.03 ± 0.01
Wild type 1.0 µg/mL CAP 0.20 ± 0.04 0.16 ± 0.04 0.07 ± 0.01
ΔtlyA – 0.20 ± 0.04 0.14 ± 0.03 0.07 ± 0.01
ΔtlyA 1.0 µg/mL CAP 0.20 ± 0.04 0.18 ± 0.03 0.15 ± 0.02
A1408G 1.0 µg/mL CAP 11.12 ± 3.51 0.86 ± 0.14 238.77 ± 39.5
ΔtlyA A1408G 1.0 µg/mL CAP 12.46 ± 3.59 1.02 ± 0.17 274.54 ± 28.5
FIGURE 1. Capreomycin affects post-transcriptional methylation in 16S rRNA and 23S rRNA.
Primer extension analysis of Cm1409∗, helix 44 (A) and Cm1920∗, helix 69 (B) in the rRNA ofM.
smegmatis wild type andM. smegmatis ΔtlyAmutant. The strains were grown in liquid culture for
20 h. Wild type strains were grown without drug and in the presence of 0.5 and 1 µg/mL capreo-
mycin. The size marker indicates positions from A1408 to C1412 and A1919 to C1925, respec-
tively. Densitometric analysis of position Cm1409 (C) and Cm1920 (D).
Nonmutational compensation of fitness cost
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of rRNA. How the A1408G mutation confers the increase in
tlyA gene expression is at present unclear, but the compensa-
tory mechanism involves a physiological alteration that in-
creases fitness and buffers the mutational effect at the
expense of reduced resistance. Thus, our data show that ex-
pression of the rRNA methylase TlyA is up-regulated when
the A1408G mutation is present, thereby partly restoring fit-
ness (the fitness cost measured as growth rate was reduced
from 10% to 5%). This increase in fitness is importantly as-
sociated with a reduced resistance to cap-
reomycin, presumably as a result of the
increased methylation of rRNA.
The observation that increased fitness
is associated with reduced capreomycin
resistance is particularly relevant with re-
gard to treatment of tuberculosis. Thus,
previous work has formulated ideas
for rationally selecting drug combina-
tions that limit resistance evolution based
on antagonistic antibiotic interactions
where resistance to one drug increases
susceptibility to another, so-called collat-
eral sensitivity (Michel et al. 2008;
Munck et al. 2014; Baym et al. 2016).
Our findings add to this framework and
suggest a new option to combat the clin-
ically highly relevant problem of MDR-
TB. MDR treatment is frequently com-
plicated by resistance development as
per the A1408G mutation (Shcherbakov
et al. 2010). As the A1408G alteration
confers cross-resistance to capreomycin,
the corresponding mutants are resistant
to both aminoglycosides and tuberacti-
nomycins (Maus et al. 2005a; Feuerriegel
et al. 2009; Jugheli et al. 2009; Akberge-
nov et al. 2011; Sirgel et al. 2012). The
A1408G mutants observed in clinical
M. tuberculosis isolates are mostly, if
not all, a result of treatment with amino-
glycosides, whereas resistance mutations
selected during treatment with capreo-
mycinmainly affect tlyA. Thus, resistance
evolution via the A1408G mutation
could be reduced by first using capreo-
mycin rather than kanamycin or amikacin in MDR TB treat-
ment. If capreomycin resistance develops, mainly due to
nonsense mutations in tlyA, it can subsequently be replaced
by an aminoglycoside as tlyA nonsense mutations do not af-
fect susceptibility to kanamycin or amikacin. However, the
loss of TlyA function would significantly increase the fitness
cost of the A1408G mutation impeding its fixation in the
population. In this context, it is relevant to note that a double
A1408G tlyA mutant has to our knowledge never been
FIGURE 2. tlyAmRNA levels measured by quantitative PCR. (A) TlyAmRNA levels inM. smeg-
matis; wild type (white bar) and A1408G (gray bar). 16S rRNA (left) and EF-Tu (right) were used
as internal controls. The average expression levels of three wild-type strains and three A1408G
strains are given, SDs are indicated, P < 0.01. (B) TlyA mRNA expression in laboratory strain
M. tuberculosisH37Rv ATCC27294. Averaged expression levels of triplicate measurements (three
wild type clones, five A1408G mutants), SDs are indicated, P < 0.01. (C) TlyAmRNA expression
in M. tuberculosis wild-type versus A1408G clinical isolates. Averaged expression levels of tripli-
cate measurements (six clinical isolates of each M. tuberculosis wild type and M. tuberculosis
A1408G). Mean and SD are given, P < 0.001. (Inset) TlyA mRNA expression at the level of indi-
vidual clinical isolates. Mean and SD are given, P < 0.01.
TABLE 5. Drug susceptibility (MIC, µg/mL) ofM. smegmatis ΔtlyA and A1408G mutant strains preincubated with 1 µg/mL capreomycin for 20 h
Genotype
Capreomycin Viomycin Amikacin
No preincubation Preincubation No preincubation Preincubation No preincubation Preincubation
ΔtlyA 32–64 32–64 8–16 16 0.25 0.25
A1408G 64–128 1024 4–8 32–64 >1024 >1024
ΔtlyA A1408G 1024 1024 32–64 32–64 >1024 >1024
Freihofer et al.
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observed in clinical isolates and it is conceivable that the
substantial fitness cost of the double mutation precludes it
from becoming fixed in the population. We searched public
genome databases (EMBL, GMTV) for M. tuberculosis iso-
lates with the A1408G mutation. We extracted genomic
data from a total of 291 M. tuberculosis A1408G mutant
strains (220 genomes EMBL database, 71 genomes GMTV
database); none of these strains carried a mutation in the
tlyA gene.
In conclusion, our results demonstrate how nonmuta-
tional compensation, i.e., a regulatory change in gene expres-
sion of the tlyA gene, can reduce the deleterious effects of a
common resistance mutation and how these effects poten-
tially can be utilized to optimize treatment regimes. It is likely
that such nongenetic compensatory mechanisms are more
common than previously thought and that an understanding
of the specific mechanisms can be used to identify regulatory
responses that are amenable to modulation by altered treat-
ment regimes and/or inhibition by drugs.
MATERIALS AND METHODS
Antibiotics
Capreomycin sulfate and amikacin sulfate were obtained from
Sigma (catalog no. C4142 and A2324, respectively); viomycin sulfate
was obtained from Tocris Bioscience (catalog no. 3787).
MIC assay
Drug susceptibility testing of M. smegmatis was done in by broth
microdilution in triplicates using twofold dilution series of antibiot-
ics, as described previously (Hobbie et al. 2007). The MIC was de-
fined as the drug concentration at which growth of the cultures
was completely inhibited after 72 h incubation of 37°C. Drug sus-
ceptibility of M. tuberculosis was assessed using the MGIT 960 in-
strumentation equipped with the TBeXiST software (Becton
Dickinson) as described previously (Springer et al. 2009).
Bacterial strains and DNA techniques
The strains and plasmids used in this study are given in
Supplemental Tables 1, 2, and 3. Clinical strains of Mycobacterium
tuberculosis were obtained from the Diagnostic Department,
Institute of Medical Microbiology, University of Zurich. The single
rRNA allelic Mycobacterium smegmatis ΔrrnB strain (SZ380) was
obtained by unmarked deletion mutagenesis (Hobbie et al. 2006,
2007) and used for all genetic constructions. Strains SZ459-461
are derivatives of SZ380 with a mutated rrn operon (A1408G) ob-
tained by site-directed mutagenesis (Shcherbakov et al. 2010). M.
smegmatis ΔrrnA ΔrrnB attB::int-hyg-rrnB (SZ633) was used for
tlyA gene inactivation. In this strain, the two endogenous rrn oper-
ons have been deleted by unmarked deletion mutagenesis, and syn-
thesis of rrn is provided by an integrative plasmid which carries the
complete rrnB operon under control of its own promoter (Hobbie
et al. 2007). A tlyA knockout mutant was generated by homologous
recombination using the gene targeting vector pZ566 followed by se-
lection on sucrose and kanamycin. Vector pZ566 was constructed by
ligating the left and right chromosomal regions of tlyA (obtained by
PCR) into a suicide vector carrying sacB and aph. Successful gene
deletion was controlled by Southern blot analysis. M. smegmatis
ΔtlyA ΔrrnA ΔrrnB attB::int-Gm-rrnB (SZ907-909) was generated
by plasmid exchange using the rrn complementing vector pH144
and selection with gentamicin. M. smegmatis ΔtlyA ΔrrnA ΔrrnB
attB::int-hyg-rrnB (SZ910-912) was obtained by plasmid exchange
in strain SZ907 using rrn complementing vector pH150 and selec-
tion with hygromycin. M. smegmatis ΔtlyA ΔrrnA ΔrrnB attB::int-
hyg-rrnB A1408G (SZ913-915) was generated from strain SZ907
by plasmid exchange using rrn complementing vector pH187 and
selection with hygromycin. Vector pH187 carries a 16S rRNA
A1408G mutation and was obtained from vector pH150 by PCR-
mediated mutagenesis.
Determination of generation time
Growth experiments were done in triplicates in 200 mL Erlenmeyer
flasks in a total volume of 50 mL of LB-Tween 0.05%. Freshly, ho-
mogeneously grown cells were picked from an agar plate, resuspend-
ed thoroughly in 1 mL of LB-Tween and diluted for inoculation,
resulting in an A600 of 0.01. The measurements were started after
overnight incubation at an A600 of approximately 0.1. The A600
was measured every 2.5 h for 12 h and generation times were
calculated.
Isolation and purification of ribosomes
Ribosomes were purified from bacterial cell pellets by sucrose gradi-
ent (10% to 40%) centrifugation as described previously (Beringer
et al. 2005; Bruell et al. 2008). Ribosome concentrations of 70S
were determined by absorption measurements on the basis of 23
pmol ribosomes per A260 unit.
Cell-free luciferase translation assays
Purified 70S ribosomes and in vitro-transcribed firefly luciferase
mRNA were used in translation reactions. Firefly luciferase mRNA
was produced using T7 RNA polymerase in vitro. A typical transla-
tion reaction mixture contained 0.21 µM 70S ribosomes, 450 ng
FIGURE 3. Generation times. M. smegmatis wild type; ΔtlyA mutant;
A1408G mutant; and ΔtlyA, A1408G double mutant. Average genera-
tion times and SDs are indicated. The average generation times were
as follows: wild type 2.99 ± 0.01, ΔtlyA 3.01 ± 0.07, A1408G 3.14 ±
0.05, ΔtlyA, A1408G 3.32 ± 0.06. Each strain was measured in triplicate;
P-values are indicated.
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mRNA, 20% (v/v) M. smegmatis S100 extract, 200 µM amino
acid mixture, 0.3 µL 50× protease inhibitor coctail (Roche) and
Ribo Lock RNase inhibitor (12 units; Promega), 0.4 mg/ml tRNAs
and 40% (v/v) commercial S30 premix without amino acids
(Promega). 1.5 µL antibiotics (final reaction concentrations between
0.01 and 1000 µM) orwater were added to themixture. The total vol-
ume of the reactionmixture was 15 µL. The reactionmixture was in-
cubated at 37°C for 30 min and stopped on ice. Finally, 75 µL
luciferase assay substrate (Promega) was added and the biolumines-
cence measured in a luminometer (Flx800; Bio-Tek Instruments).
The IC50 is defined as drug concentration required to inhibit synthe-
sis of active luciferase to 50%.
Ribosomal RNA methylation
rRNA methylations at 16S rRNA position C1409 (h44) and at 23S
rRNA position C1920 (h69) were determined by primer extension
analysis. Ribosomal RNA was isolated from purified ribosomes ob-
tained by sucrose gradient centrifugation using TRIzol reagent (Life
Technologies). Ribosomal RNA concentrations were determined by
absorption measurements at A260 nm. Primers 5′-GGTGTTACC
GACTTTCATG-3′ for h44 and 5′-GGAATTTCGCTACC TTAG-3′
for h69 were ordered from Microsynth and radiolabeled with γ
32-ATP (Hartman Analytics, catalog no. FP-501) using the follow-
ing reaction: 2 µL T4-polynucleotide kinase (10 U/µL; Fermentas), 2
µL 10× buffer A PNK (Fermentas), 1.5 µL (0.37 MBq/µl) γ 32-ATP,
2 µL 10 mM primer and 12.5 µL water. The reaction mixture was
incubated at 37°C for 30 min followed by column purification using
Quick spin columns (Sephadex G-25, fine, Roche).
For primer annealing, 5 µL radiolabeled primer, 2 µL rRNA (0.5
µg/µL) and 7.5 µL water were heated up at 90°C for 30 sec, followed
by 15 min incubation at room temperature. For primer ex-
tension reactions, the following components were added and
incubated at 50°C for 1 h: 0.5 µL AMV reverse transcriptase (20
U/µL; Fermentas), 4 µL 5× AMV reverse transcriptase buffer
(Fermentas), and 1 µL dNTP mixture (10 mM dATP, 10 mM
dCTP, 10 mM dTTP, 0.1 µM dGTP). After the primer extension re-
action, samples were purified with the Quick spin columns
(Sephadex G-25, fine, Roche). Subsequently, the samples were heat-
ed at 95°C for 5 min in formamide sample buffer (95% formamide,
5% saturated bromphenol blue solution) and run on polyacryl-
amide gels (20% acylamide/bis-acrylamide 19:1, 8 M urea) using
TBE running buffer (89 mM Tris, 89 mM boric acid, 2 mM
EDTA, pH 8.0). Gels were dried and exposed to phosphor imaging
screens (Kodak SO230). The screens were scanned with fluorescent
image analyzer (Fujifilm FLA-5100). The intensity of bands was
quantified using Aida Image Analyser software.
Determination of mRNA expression
M. smegmatis strains were grown in liquid culture (LB-Tween) and
harvested in logarithmic growth at an OD600 0.2–0.4.M. tuberculosis
clinical isolates were grown in liquid culture (7H9 OHDC) and har-
vested in logarithmic growth at an OD600 0.3–0.35. RNA was ex-
tracted using TRIzol extraction (Life Technologies) and reverse
transcribed using the High Capacity RNA-to-cDNA kit (Applied
Biosystems) according to themanufacturer’s instructions. For quan-
titative PCR, the Quantitect SYBR Green PCR kit (Qiagen) was used
together with the 7500 Fast Real-Time PCR System (Applied
Biosystems). Primers for M. smegmatis were:
1. tlyA: forward 5′-GTGTCAGATCGCGAGGTTCT-3′, reverse 5′-
GGAGGATTCACCGAGGTTCT-3′;
2. 16S rRNA: forward 5′-GCGTTGTTCGTGAAAACTCA-3′, re-
verse 5′-CCTCCTGATATCTGCGCATT-3′;
3. EF-Tu: forward 5′-GACAAGTTCCCCGATTTGA 3′, reverse 5′-
GTGTGCGTAGTGACGCTTGT-3′.
Primers for M. tuberculosis were:
1. tlyA: forward 5′-GTTCATCTCGTTGGCTACC-3′, reverse 5′-
CTTCACCAGTGGAACGATA-3′;
2. 16S rRNA: forward 5′-GCAGATATCAGGAGGAACA-3′, reverse
5′-GGACATCCAGGGTATCTAATC-3′.
For relative quantification of tlyA gene expression, 16S rRNA and
EF-Tu served as reference. CT-values were calculated according to
Pfaffl (Pfaffl 2001). Three biological replicates were run in triplicates
each and means and SDs were calculated. Every biological replicate
contained a negative control without reverse transcription. Relative
tlyA mRNA expression was calculated by relating the individual ex-
pression level to the average values of wt isolates.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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